Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Affitech and Omeros in antibody development deal

This article was originally published in Scrip

Executive Summary

Norway's Affitech and Omeros have signed an agreement to discover and develop fully human antibodies against inflammatory diseases for Omeros's MASP-2 (mannan-binding lectin-associated serine protease-2) programme. The agreement will advance Omeros's programme, and allow Affitech to expand a portfolio that is mainly focused on oncology. The US company will pay a technology-access fee, milestone payments and royalties on net sales. No further details were released owing to pre-IPO restrictions; Omeros filed an IPO with the US SEC to float on Nasdaq earlier this year (Scrip Online, January 14th, 2008). It holds the worldwide rights related to MASP-2 from the UK's University of Leicester and its collaborator, the Medical Research Council at Oxford University. They cover antibodies targeting MASP-2 and the therapeutic applications for those antibodies, MASP-2 is required for the function of a principal complement activation pathway, known as the lectin pathway. Its abnormal function is associated with a wide range of inflammatory diseases including macular degeneration, rheumatoid arthritis and cardiovascular and renal ischaemia-reperfusion therapy. Antibody therapies represent one of the fastest-growing sectors within the pharmaceutical industry, with sales forecast to reach $30 billion in 2008, according to Business Insight.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts